Protagenic Therapeutics, Inc.\new (PTIX): Total Liabilities
$1.03M
As of 2026-03-31
$1.07M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $1.03M | -79.5% | 2026-08-14, Balance as of period end |
| 2025-03-31 | $5.04M | n/a | 2026-08-14, Balance as of period end |
| 2024-12-31 | $942.8K | +43.9% | 2025-03-31, Balance as of period end |
| 2023-12-31 | $655.3K | -41.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $1.12M | +0.2% | 2024-05-14, Balance as of period end |
| 2021-12-31 | $1.12M | -44.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $2.03M | +37.4% | 2022-04-07, Balance as of period end |
| 2019-12-31 | $1.48M | +62.7% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $907.8K | n/a | 2020-04-29, Balance as of period end |
| No annual figure between 2015-06-30 and 2018-12-31. | |||
| 2015-06-30 | $704.0K | +122.8% | 2015-09-25, Balance as of period end |
| 2014-06-30 | $316.0K | n/a | 2015-09-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Protagenic Therapeutics, Inc.\new (PTIX) | 2026-03-31 | $1.03M | -79.5% |
| Bio-Path Holdings, Inc. (BPTH) | 2024-12-31 | $3.73M | +34.2% |
| Pulmatrix, Inc. (PULM) | 2025-12-31 | $329.0K | -67.0% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $1.57M | +30.1% |
| Cadrenal Therapeutics, Inc. (CVKD) | 2025-12-31 | $1.59M | -40.8% |
| Hepion Pharmaceuticals, Inc. (HEPA) | 2025-12-31 | $402.4K | -88.4% |
| InMed Pharmaceuticals Inc. (INM) | 2026-06-30 | $1.96M | -8.9% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $813.0K | +17.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.10M | +34.7% |
Compare PTIX, BPTH, PULM, LEXX side by side · Screen every company in Pharmaceutical Preparations ↗